Sonal Patel

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 746 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

Florence I. Raynaud, Suzanne A. Eccles, Paul A. Clarke et al. · Cancer Research · 2007 · 352 citations · Full text

Medicine, Oncology, Pharmacology +10

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Florence I. Raynaud, Suzanne A. Eccles, Sonal Patel et al. · Molecular Cancer Therapeutics · 2009 · 274 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Jeffrey J. Wallin, Kyle A. Edgar, Jane Guan et al. · Molecular Cancer Therapeutics · 2011 · 228 citations

Medicine, Oncology, Pharmacology +16

Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte Culture

Leslie J. Dickmann, Sonal Patel, Dan A. Rock et al. · Drug Metabolism and Disposition · 2011 · 190 citations

Medicine, Pharmacology, Biochemical Pharmacology +16